Aquafit delivers a new approach to intimate care, vaginal wellness and pleasure.
For women, by women.
Aquafit all-in-one Intimate Gel Stick couples the benefits of vaginal dilation therapy with natural extracts that hydrate, relax, rejuvenate and balance vaginal PH, for pure intimate care.
Made from water and all natural, nontoxic plant-based materials, the self-lubricating Intimate Gel Stick adapts to individual women’s anatomy, while achieving deep delivery of beneficial active agent for intimate wellness.
Aquafit Intimate Gel Sitck product range – Pre, Bliss, Bio and Revive – provide relief for women who experience vaginal dryness, atrophy and discomfort, while decreasing tension, enhancing sensual pleasure and heightening sexual sensations.
ConTIPI Medical develops non-invasive and disposable vaginal devices for women with Pelvic Floor Disorders. All devices are inserted vaginally by the user herself, at her home environment, within a disposable applicator. Within the vagina the device opens to provide support. By the end of use, or at the user’s will, a pull of a string collapses the device back into small dimensions, for disposal.
Initial device, for management of stress urinary Incontinence, was sold to Kimberly Clark Worldwide Inc, and is already for sale in North America under the name Poise Impressa.
Current solution, for Pelvic Organ Prolapse, the ProVate Device, which follows the same concept, is ready for the market, has a CE Mark, and is now under regulatory consideration in the US.
MAS Holdings is South Asia’s largest manufacturer of intimate wear and sportswear, with over 30 years of experience working alongside leading apparel brands in the US and EU. From a company that began as a bra manufacturer, FemTech@MAS was a natural fit 5 years ago. FemTech combines knowledge of the female body with unparalleled expertise in fabrics, textiles and innovation to launch functional, wellness-oriented apparel solutions that champion female consumer needs from menarche to menopause.
Socio-cultural norms also often consider women’s healthcare issues as taboo subjects & we are passionate about breaking these taboos.
Ferring Pharmaceuticals is a Swiss-based, research-driven, specialty biopharmaceutical group committed to helping people live better lives. Founded in 1950, it is a leader in reproductive medicine/women’s health, and in specialty areas within gastroenterology and urology. Ferring employs more than 6,500 people and markets its products in 110 countries, and acquired Bio-Technology General (BTG) with its biotech capabilities in 2005.
In Israel, Ferring Holding Ltd. (FHL) plays a pivotal role in Ferring’s global innovation activities. Founded in 2016, FHL collaborates with local academics, physicians and entrepreneurs to deliver life-changing biopharmaceuticals and medical technologies. Its goal is to foster local innovations in biotechnology and other disciplines, including new areas such as mobile health, in Ferring’s key therapeutic areas.
One of the fastest growing academic health institutions in the United States, Jefferson combines both Thomas Jefferson University and Jefferson Health, headquartered in Philadelphia. The university is home to Sidney Kimmel Medical College, founded in 1824 as Jefferson Medical College, as well as 10 colleges and three schools focused on professional programs from health to design, fashion, and architecture. The university was ranked in the top 20 for innovation by the Brookings Institution, and 5th in its region for innovation by U.S. News and World Report. Jefferson Health includes 14 hospitals, more than 40 outpatient and urgent care locations, the NCI-designated Sidney Kimmel Cancer Center and Magee Rehabilitation. It is nationally ranked in 10 speciality areas by US News & World Report. We are 30,000+ people reimagining health care, education and discovery.
Gynica is changing the culture of gynecological treatment through clinically-proven, cannabinoid-based solutions.
Gynica is a medical company at the forefront of therapeutic cannabis research in the field of women’s health. Our team develops medical treatments based on innovative technology and an advanced understanding of the pharmacological effects of cannabinoids that target specifically female symptoms and diseases.
We believe that cannabinoids are the missing piece in the treatment of gynecological disorders –
Scientific research has shown that the cannabis plant is unique for women —after the brain, the female reproductive system is the organ with the most endocannabinoid receptors in the human body.
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).
For years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the sectors we operate in.
Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, providing end-to-end technology transfer services. Mor helps inventors to translate new ideas in the medical, pharmaceutical, diagnostics, medical IT and biotechnology fields into solutions available to health caregivers and patients.
Mor’s commercialization portfolio comprises over 100 different projects and companies in various stages of development, from pre-seed to advanced stage companies. The intellectual property is conceived and developed by professionals working at our 14 hospitals and around 2000 clinics across the country, including Beilinson, Meir, Kaplan, Carmel, Soroka, Ha-Emek, and Schneider medical centers.
The clinic of reproductive medicine NADIYA successfully helps people to become parents for over 13 years. More than 5084 children were born due to the treatment of infertility in the clinic by using advanced methods of assisted reproductive technology.
In 2017, DL-NADIYA consortium united the team of US and Ukrainian scientists who have combined experience in molecular genetics, embryology and human reproduction to develop the newest methods for achieving the pregnancy with a healthy baby in women with the high risk of mitochondrial pathology in their offspring, as well as in complicated cases of infertility forms with high genetic risk.